Accordingly, agents that raise cAMP promote the clearance of disease-associated Tau mutants in cells (13), and in a mouse model of frontotemporal dementia, where they not only increased proteasome activity but also lowered the levels of phospho-tau in the brain (14, 16). The gene discussed is MAPT; the disease is frontotemporal dementia.